Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy.

Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Edwards KL, Snapinn KW, Goldstein DS, Shi M, Zhang J.

Am J Pathol. 2011 Apr;178(4):1509-16. doi: 10.1016/j.ajpath.2011.01.006.

2.

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG.

Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X. Erratum in: Lancet Neurol. 2011 Apr;10(4):297.

PMID:
21317042
3.

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression.

Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D, Zhang J.

Ann Neurol. 2011 Mar;69(3):570-80. doi: 10.1002/ana.22311. Epub 2011 Mar 11.

4.

Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.

Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I.

J Alzheimers Dis. 2014;38(1):63-73. doi: 10.3233/JAD-130995.

PMID:
23948928
5.

Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease.

Daborg J, Andreasson U, Pekna M, Lautner R, Hanse E, Minthon L, Blennow K, Hansson O, Zetterberg H.

J Neural Transm (Vienna). 2012 Jul;119(7):789-97. doi: 10.1007/s00702-012-0797-8. Epub 2012 Apr 10.

PMID:
22488444
6.

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.

Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E.

J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1080-6. doi: 10.1136/jnnp.2009.199950. Epub 2010 Jun 14.

PMID:
20547614
7.

Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy.

Konings CH, Kuiper MA, Teerlink T, Mulder C, Scheltens P, Wolters EC.

J Neurol Sci. 1999 Oct 15;168(2):112-5.

PMID:
10526192
8.

CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.

Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J.

Mov Disord. 2010 Nov 15;25(15):2682-5. doi: 10.1002/mds.23287.

9.

Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders.

Nutu M, Zetterberg H, Londos E, Minthon L, Nägga K, Blennow K, Hansson O, Ohrfelt A.

Dement Geriatr Cogn Disord. 2013;36(1-2):99-110. doi: 10.1159/000353442. Epub 2013 Jul 9.

PMID:
23860354
10.

Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.

Skillbäck T, Farahmand BY, Rosén C, Mattsson N, Nägga K, Kilander L, Religa D, Wimo A, Winblad B, Schott JM, Blennow K, Eriksdotter M, Zetterberg H.

Brain. 2015 Sep;138(Pt 9):2716-31. doi: 10.1093/brain/awv181. Epub 2015 Jun 30.

11.

Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease.

Beyer MK, Alves G, Hwang KS, Babakchanian S, Bronnick KS, Chou YY, Dalaker TO, Kurz MW, Larsen JP, Somme JH, Thompson PM, Tysnes OB, Apostolova LG.

Mov Disord. 2013 Mar;28(3):302-10. doi: 10.1002/mds.25282. Epub 2013 Feb 13.

12.

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Håkan W, Decraemer H, Någga K, Minthon L, Londos E, Vanmechelen E, Holmberg B, Zetterberg H, Blennow K, Hansson O.

Arch Neurol. 2012 Nov;69(11):1445-52.

PMID:
22925882
13.

Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.

Bäckström DC, Eriksson Domellöf M, Linder J, Olsson B, Öhrfelt A, Trupp M, Zetterberg H, Blennow K, Forsgren L.

JAMA Neurol. 2015 Oct;72(10):1175-82. doi: 10.1001/jamaneurol.2015.1449.

PMID:
26258692
14.

Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease.

Kristofikova Z, Ricny J, Kolarova M, Vyhnalek M, Hort J, Laczo J, Sirova J, Ripova D.

J Alzheimers Dis. 2014;42 Suppl 3:S91-8. doi: 10.3233/JAD-132393.

PMID:
24670397
15.

Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.

Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P.

Biol Psychiatry. 2008 Nov 15;64(10):850-5. doi: 10.1016/j.biopsych.2008.02.016. Epub 2008 Apr 8.

PMID:
18395699
16.

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.

Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, El-Agnaf O.

Mov Disord. 2011 Jul;26(8):1428-35. doi: 10.1002/mds.23670. Epub 2011 Apr 5.

PMID:
21469206
17.

Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease.

Přikrylová Vranová H, Mareš J, Hluštík P, Nevrlý M, Stejskal D, Zapletalová J, Obereigneru R, Kaňovský P.

J Neural Transm (Vienna). 2012 Mar;119(3):353-62. doi: 10.1007/s00702-011-0708-4. Epub 2011 Sep 4.

PMID:
21892760
18.

Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia.

Compta Y, Ibarretxe-Bilbao N, Pereira JB, Junqué C, Bargalló N, Tolosa E, Valldeoriola F, Muñoz E, Camara A, Buongiorno M, Martí MJ.

Parkinsonism Relat Disord. 2012 Sep;18(8):941-7. doi: 10.1016/j.parkreldis.2012.04.028. Epub 2012 May 15.

PMID:
22595621
19.

Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's Disease.

Bach JP, Gold M, Mengel D, Hattesohl A, Lubbe D, Schmid S, Tackenberg B, Rieke J, Maddula S, Baumbach JI, Nell C, Boeselt T, Michelis J, Alferink J, Heneka M, Oertel W, Jessen F, Janciauskiene S, Vogelmeier C, Dodel R, Koczulla AR.

PLoS One. 2015 Jul 13;10(7):e0132227. doi: 10.1371/journal.pone.0132227. eCollection 2015.

20.

Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease.

Liguori C, Romigi A, Nuccetelli M, Zannino S, Sancesario G, Martorana A, Albanese M, Mercuri NB, Izzi F, Bernardini S, Nitti A, Sancesario GM, Sica F, Marciani MG, Placidi F.

JAMA Neurol. 2014 Dec;71(12):1498-505. doi: 10.1001/jamaneurol.2014.2510.

PMID:
25322206
Items per page

Supplemental Content

Write to the Help Desk